Government panel recommends emergency approval for SII’s Covovax for seven-11 year olds

An expert panel of India’s central drug authority last week recommended granting Emergency Use Authorisation (EUA) to Serum Institute’s Covovax for children aged seven to 11 years, official sources said.

The recommendation has been sent to the Drugs Controller General of India (DCGI) for final approval. The application for EUA was submitted by Prakash Kumar Singh, Director, Government and Regulatory Affairs, Serum Institute of India (SII), on 16th March.

“The Subject Expert Committee (SEC) on COVID-19 of the CDSCO deliberated on the EUA application of SII and recommended granting Emergency Use Authorisation for Covovax for children aged seven to 11 years,” an official source said.

The expert panel, in its last meeting in April, had sought more data from the Pune-based firm over the application.

Edits by EP News Bureau